Discussion
NSCLC
BRAIN METASTASES, NSCLC
In this phase 3 randomized clinical trial, our results revealed that gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS in patients with untreated NSCLC Recently, EGFR-TKI combination therapy has shown superior efficacy than EGFR-TKI treatment alone in the NEJ009.The third-generation EGFR-TKI osimertinib has demonstrated longer PFS and OS and better central nervous system permeability than first-generation EGFR-TKIs in the FLAURA study.In the NEJ009 study, individual OS data on a subgroup with brain metastases were not reported, and the OS benefit with gefitinib plus chemotherapy was not significant, with a limited sample size.For the mechanism of acquired resistance to EGFR-TKI combination therapy, the NEJ026 study reported that erlotinib combined with bevacizumab had a similar percentage of Radiotherapy has been the traditional method for localized management of brain metastases. The optimal sequence or combination of BRT and targeted therapy in The genomic context of the driver 